GlassScriptPhysician profile
Lisa Anderson
NPI 1861943615
$3,037.33
in general payments reported to CMS, 2019-2025
23 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $935 · 2022: $392 · 2023: $642 · 2024: $816 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,702 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.90 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.79 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $361.21 | 2021-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $328.97 | 2021-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $294.73 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $250.46 | 2021 | |
| Tris Pharma INC | $177.74 | 2021-2024 | Dyanavel Xr |
| Lundbeck LLC | $122.27 | 2021-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.40 | 2021-2023 | |
| Vanda Pharmaceuticals INC. | $112.17 | 2023-2025 | Fanapt, Hetlioz |
| Corium, LLC | $106.61 | 2022-2024 | Azstarys |
| Alkermes, INC. | $77.94 | 2023-2024 | Lybalvi |
| Bausch Health US, LLC | $54.87 | 2025 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $53.76 | 2023-2024 | Quviviq |
| Avion Pharmaceuticals | $41.28 | 2023 | Methylphenidate Hydrochloride |
| Teva Pharmaceuticals USA, INC. | $40.52 | 2024 | Austedo Xr, Uzedy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $33.36 | 2023 | Auvelity |
| Ironshore Pharmaceuticals INC. | $30.21 | 2022-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $28.99 | 2024 | Qelbree |
| Neurocrine Biosciences, INC. | $21.75 | 2025 | |
| Neuronetics, INC. | $20.65 | 2021 | |
| Neos Therapeutics, LP | $18.18 | 2021 | |
| Collegium Pharmaceutical, INC. | $17.85 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $14.62 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.